Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
WES of the HCC tissue uncovered somatic driver mutations in the beta-catenin (CTNNB1) and nuclear-factor-erythroid-2-related-factor-2 (NFE2L2) genes.
|
25016225 |
2014 |
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our study demonstrates the importance of CTNNB1 mutations and NFE2L2-KEAP1 pathway activation in HB development and defines loss of genomic stability and TERT promoter mutations as prominent characteristics of aggressive HB with HCC features.
|
25135868 |
2014 |
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The NFE2L2-KEAP1 and MLL pathways are recurrently mutated in multiple cohorts of HCC.
|
23728943 |
2013 |
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
High-throughput short-read sequencing of exomes and whole cancer genomes in multiple human hepatocellular carcinoma (HCC) cohorts confirmed previously identified frequently mutated somatic genes, such as TP53, CTNNB1 and AXIN1, and identified several novel genes with moderate mutation frequencies, including ARID1A, ARID2, MLL, MLL2, MLL3, MLL4, IRF2, ATM, CDKN2A, FGF19, PIK3CA, RPS6KA3, JAK1, KEAP1, NFE2L2, C16orf62, LEPR, RAC2, and IL6ST.
|
24379610 |
2013 |
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that PB induced progression from HCA to HCC in <i>Ogg1</i><sup>-/-</sup> mice, due to persistent accumulation of DNA oxidative base modifications and suppression of Nrf2-mediated oxidative stress response, resulting in significant elevation of cell proliferation.
|
28785378 |
2017 |
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model.
|
30279623 |
2018 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutations of Keap1 occurred at a much lower frequency in both preneoplastic lesions and HCCs and were mutually exclusive with those of Nrf2.
|
25783764 |
2015 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma.
|
30909929 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Importantly, similar aggregates were identified in more than 25% of human hepatocellular carcinomas (HCC), and induction of Nrf2 target genes was recognized in most of these tumors.
|
21482715 |
2011 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results suggested that apigenin sensitizes BEL-7402/ADM cells to doxorubicin through miR-101/Nrf2 pathway, which furtherly supports apigenin as a potential chemo-sensitizer for hepatocellular carcinoma.
|
29137246 |
2017 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
An inhibitor of phosphorylated p62-dependent Nrf2 activation suppresses the proliferation and anticancer agent tolerance of HCC.
|
27345495 |
2016 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These emerging molecular mechanisms and the therapeutic perspective of targeting Nrf2-p62 interaction in HCC are discussed in this paper along with the prognostic value of autophagy in this type of cancer.
|
29274776 |
2018 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
All of our data confirmed that oxidative stress-mediated mitochondrial apoptosis (especially the Nrf-2/HO-1 pathway) is responsible for 5h2c-induced HCC damage.
|
30055129 |
2018 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using microarray, quantitative reverse transcription-PCR, and RNA-seq technologies, we examined the gene expression induced by PB125 in HepG2 (hepatocellular carcinoma) cells, including canonical Nrf2-regulated genes, noncanonical Nrf2-regulated genes, and genes which appear to be regulated by non-Nrf2 mechanisms.
|
31058853 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This review summarizes the role and mechanism(s) of action of Nrf2 dysregulation in HCC and therapeutic options that can be employed to modulate this transcription factor.
|
30513925 |
2018 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our study showed that miR-141 plays a key role in 5-FU resistance by down-regulating Keap1 expression, thereby reactivating the Nrf2-dependent antioxidant pathway, which may serve as a potential target for overcoming 5-FU resistance in hepatocellular carcinoma cells.
|
25896253 |
2015 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, the results first suggested that lower expression of miR-340 is involved in the development of CDDP resistance in hepatocellular carcinoma cell line, at least partly due to regulating Nrf2-dependent antioxidant pathway.
|
25556489 |
2014 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, we conducted this research to examine the therapeutic effects of nicotinamide against hepatocellular carcinoma (HCC) both in vivo and in vitro through affecting IGF-1 and the balance between PKB and Nrf2.
|
30784932 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overactivated Nrf2 was required for hepatoma growth in DEN-induced HCC.
|
28655791 |
2017 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrated that AMPK activator AICAR, in contrary to the A769662 allosteric activator, induces Nrf2 activation and concomitantly modulates the basal redox state of the hepatocarcinoma cells.
|
25058527 |
2014 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC.
|
22561517 |
2012 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis.
|
31386899 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, the present investigation suggest that the NRAL/miR-340-5p/Nrf2 axis mediates cisplatin resistance in HCC, which may provide novel targets for overcoming cisplatin resistance in hepatocellular carcinoma cells.
|
30030687 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, phosphorylation of KHK-A S80 and p62 S28 and nuclear accumulation of Nrf2 are positively correlated in human HCC specimens and with poor prognosis of patients with HCC.
|
31032410 |
2019 |